This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Midatech Pharma PLC
Description: MTX102 makes use of Midatech’s primary platform technology, using GNPs, which are known to be both safe and inert in vivo. In this vaccine, which has applicability in oncology, GNPs are chemically bound to small antigens which generate a tolerogenic response when injected into the skin, turning down the immune response against the insulin producing cells, which causes type 1 diabetes.
Additional information available to subscribers only: